Renaissance Technologies LLC raised its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 54.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 285,700 shares of the company's stock after purchasing an additional 101,100 shares during the quarter. Renaissance Technologies LLC owned 0.41% of Zymeworks worth $4,183,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its holdings in Zymeworks by 6.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company's stock worth $214,000 after acquiring an additional 940 shares in the last quarter. FMR LLC boosted its stake in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after purchasing an additional 1,525 shares in the last quarter. Stifel Financial Corp increased its holdings in Zymeworks by 2.1% during the third quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock valued at $924,000 after buying an additional 1,540 shares during the period. Teacher Retirement System of Texas raised its stake in Zymeworks by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company's stock worth $201,000 after buying an additional 2,216 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in Zymeworks by 480.2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock worth $41,000 after buying an additional 2,324 shares during the period. 92.89% of the stock is owned by hedge funds and other institutional investors.
Zymeworks Trading Up 0.6 %
Shares of NYSE ZYME traded up $0.07 during trading on Thursday, reaching $12.52. The company had a trading volume of 353,171 shares, compared to its average volume of 618,920. The stock has a market capitalization of $871.10 million, a PE ratio of -8.35 and a beta of 1.18. The stock has a 50-day moving average price of $12.22 and a two-hundred day moving average price of $13.51. Zymeworks Inc. has a twelve month low of $7.97 and a twelve month high of $17.70.
Insider Activity
In related news, Director Ecor1 Capital, Llc acquired 4,397 shares of the stock in a transaction dated Monday, March 31st. The shares were bought at an average cost of $11.75 per share, for a total transaction of $51,664.75. Following the purchase, the director now owns 17,259,548 shares in the company, valued at approximately $202,799,689. This trade represents a 0.03 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired a total of 1,350,347 shares of company stock valued at $16,137,499 over the last quarter. Company insiders own 1.92% of the company's stock.
Wall Street Analyst Weigh In
ZYME has been the subject of several research analyst reports. Citigroup increased their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, March 7th. HC Wainwright upped their target price on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Finally, Lifesci Capital began coverage on shares of Zymeworks in a research note on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $21.00.
Check Out Our Latest Stock Report on ZYME
About Zymeworks
(
Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Articles
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
